Newsroom

News and developments from Affinia Therapeutics

For media inquiries: media@affiniatx.com.

  • Press Releases
  • Presentations

Press Release - May 28, 2024

Affinia Therapeutics to Participate in the 2024 Jefferies Global Healthcare Conference

Read More

Press Release - May 10, 2024

Affinia Therapeutics Presents Preclinical Data for Genetic Cardiomyopathy and Sporadic ALS Programs with Novel Cardiotropic and BBB-Penetrant AAV Capsids at the American Society of Gene & Cell Therapy 2024 Annual Meeting

Read More

Press Release - April 22, 2024

Affinia Therapeutics to Present Data on Novel Cardiotropic and BBB-Penetrant AAV Capsids and Preclinical Efficacy and Safety in Genetic Cardiomyopathies and Sporadic ALS at the American Society of Gene & Cell Therapy 2024 Annual Meeting

Read More

Press Release - Oct 24, 2023

Affinia Therapeutics to Present Preclinical Data on Novel AAV Capsids at the 30th European Society of Gene and Cell Therapy 2023 Annual Congress

Read More

Press Release - May 18, 2023

Affinia Therapeutics Presents New Preclinical Data on Novel AAV Capsids for Skeletal Muscle, Cardiac Muscle, and CNS at the American Society of Gene & Cell Therapy 26TH Annual Meeting

Read More

Press Release - May 3, 2023

Affinia Therapeutics to Present New Data at the American Society of Gene and Cell Therapy Annual Meeting

Read More

Press Release – May 16, 2022

Affinia Therapeutics Presents New Data at American Society of Gene and Cell Therapy Annual Meeting

Read More

Press Release – March 8, 2022

Affinia Therapeutics Strengthens Leadership Team with Appointment of Diana M. Brainard, M.D., to the Board of Directors

Read More

Press Release – December 14, 2021

Affinia Therapeutics Appoints Thomas Leggett as Chief Financial Officer

Read More

Press Release – October 6, 2021

Affinia Therapeutics Appoints Carole Faig to Board of Directors

Read More

Press Release – September 8, 2021

Affinia Therapeutics Announces Indications for Lead Gene Therapy Programs to Advance the Treatment of Neurologic and Neuro-oncologic Diseases supported by Multi-Year Manufacturing Agreement with Lonza Group

Read More

Press Release – July 20, 2021

Affinia Therapeutics Announces Collaboration with the Institute of Molecular and Clinical Ophthalmology Basel (IOB) To Rationally Design Novel CNS Promoters for Gene Therapy

Read More

Press Release – May 13, 2021

Affinia Therapeutics Presents New Data and Updates on AAV Platform at American Society of Gene and Cell Therapy Annual Meeting

Read More

Press Release – May 3, 2021

Affinia Therapeutics Closes $110 Million Series B Financing

Read More

Press Release – April 27, 2021

Affinia Therapeutics to Present New Data and Updates on AAV Platform at the American Society of Gene and Cell Therapy Annual Meeting

Read More

Press Release – February 17, 2021

Affinia Therapeutics Announces Addition of Gene Therapy Scientific and Medical Experts to Leadership Team to Advance Novel Gene Therapy Platform and Programs to the Clinic

Read More

Press Release – June 8, 2020

Affinia Therapeutics Announces Appointment of Elliott Sigal, M.D., Ph.D. to the Company’s Board of Directors

Read More

Press Release – April 27 2020

Vertex Pharmaceuticals and Affinia Therapeutics Establish Multi-Year Collaboration to Discover and Develop Novel AAV Capsids for Genetic Therapies

Read More

Press Release – March 31, 2020

Affinia Therapeutics Raises $60M in Series A Financing to Advance Rational Design AAV Platform and Transformative Gene Therapies

Read More